Dantrolene, sodium saltCa2+ release inhibitor CAS# 14663-23-1 |
2D Structure
- Daclatasvir (BMS-790052)
Catalog No.:BCC2533
CAS No.:1214735-16-6
- MK-5172 hydrate
Catalog No.:BCC1763
CAS No.:1350462-55-3
- MK-5172
Catalog No.:BCC1762
CAS No.:1350514-68-9
- MK-5172 sodium salt
Catalog No.:BCC1765
CAS No.:1425038-27-2
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Simeprevir
Catalog No.:BCC1949
CAS No.:923604-59-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 14663-23-1 | SDF | Download SDF |
PubChem ID | 6604100 | Appearance | Powder |
Formula | C14H9N4NaO5 | M.Wt | 336.23 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in DMSO | ||
Chemical Name | sodium;3-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-2-oxo-4H-imidazol-5-olate | ||
SMILES | C1C(=NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O-].[Na+] | ||
Standard InChIKey | KSRLIXGNPXAZHD-HAZZGOGXSA-M | ||
Standard InChI | InChI=1S/C14H10N4O5.Na/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22;/h1-7H,8H2,(H,16,19,20);/q;+1/p-1/b15-7+; | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibits release of Ca2+ from sarcoplasmic reticulum via inhibition of ryanodine receptor (RYR) channels. Displays selectivity for RYR1 and RYR3 over RYR2. Protective against the effects of a variety of conditions and agents, including excitatory amino acids. Skeletal muscle relaxant and neuroprotectant. |
Dantrolene, sodium salt Dilution Calculator
Dantrolene, sodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9742 mL | 14.8708 mL | 29.7415 mL | 59.4831 mL | 74.3539 mL |
5 mM | 0.5948 mL | 2.9742 mL | 5.9483 mL | 11.8966 mL | 14.8708 mL |
10 mM | 0.2974 mL | 1.4871 mL | 2.9742 mL | 5.9483 mL | 7.4354 mL |
50 mM | 0.0595 mL | 0.2974 mL | 0.5948 mL | 1.1897 mL | 1.4871 mL |
100 mM | 0.0297 mL | 0.1487 mL | 0.2974 mL | 0.5948 mL | 0.7435 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,6-Dimethoxybenzoic acid
Catalog No.:BCN1651
CAS No.:1466-76-8
- 2-Cyclopropyl-3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)quinoline
Catalog No.:BCC8572
CAS No.:146578-99-6
- Fmoc-Gly(allyl)-OH
Catalog No.:BCC3156
CAS No.:146549-21-5
- Tyrphostin AG 1296
Catalog No.:BCC1195
CAS No.:146535-11-7
- WR 1065
Catalog No.:BCC2417
CAS No.:14653-77-1
- Complanatoside A
Catalog No.:BCN6282
CAS No.:146501-37-3
- 1-Methylpsilocin
Catalog No.:BCC7536
CAS No.:1465-16-3
- Pralatrexate
Catalog No.:BCC2304
CAS No.:146464-95-1
- Camaric acid
Catalog No.:BCN1650
CAS No.:146450-83-1
- Flavopiridol
Catalog No.:BCC1577
CAS No.:146426-40-6
- Lactose
Catalog No.:BCN8387
CAS No.:14641-93-1
- Desmethylrocaglamide
Catalog No.:BCN7735
CAS No.:146408-78-8
- H-Trp(Boc)-OH
Catalog No.:BCC3115
CAS No.:146645-63-8
- SR 2640 hydrochloride
Catalog No.:BCC7180
CAS No.:146662-42-2
- (RS)-MCPG
Catalog No.:BCC6610
CAS No.:146669-29-6
- SR 11237
Catalog No.:BCC7681
CAS No.:146670-40-8
- Hybridaphniphylline A
Catalog No.:BCN7042
CAS No.:1467083-07-3
- Hybridaphniphylline B
Catalog No.:BCN7045
CAS No.:1467083-09-5
- Daphnicyclidin I
Catalog No.:BCN7038
CAS No.:1467083-10-8
- ZD 7155 hydrochloride
Catalog No.:BCC5734
CAS No.:146709-78-6
- Boc-D-Phe(4-CN)-OH
Catalog No.:BCC3183
CAS No.:146727-62-0
- N-desmethyldauricine
Catalog No.:BCC8217
CAS No.:146763-55-5
- Y-29794 oxalate
Catalog No.:BCC5795
CAS No.:146794-84-5
- 2-Bromo-1-(3-thienyl)-1-ethanone
Catalog No.:BCN2657
CAS No.:1468-82-2
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.[Pubmed:11278295]
J Biol Chem. 2001 Apr 27;276(17):13810-6.
As an inhibitor of Ca(2+) release through ryanodine receptor (RYR) channels, the skeletal muscle relaxant dantrolene has proven to be both a valuable experimental probe of intracellular Ca(2+) signaling and a lifesaving treatment for the pharmacogenetic disorder malignant hyperthermia. However, the molecular basis and specificity of the actions of dantrolene on RYR channels have remained in question. Here we utilize [(3)H]ryanodine binding to further investigate the actions of dantrolene on the three mammalian RYR isoforms. The inhibition of the pig skeletal muscle RYR1 by dantrolene (10 microm) was associated with a 3-fold increase in the K(d) of [(3)H]ryanodine binding to sarcoplasmic reticulum (SR) vesicles such that dantrolene effectively reversed the 3-fold decrease in the K(d) for [(3)H]ryanodine binding resulting from the malignant hyperthermia RYR1 Arg(615) --> Cys mutation. Dantrolene inhibition of the RYR1 was dependent on the presence of the adenine nucleotide and calmodulin and reflected a selective decrease in the apparent affinity of RYR1 activation sites for Ca(2+) relative to Mg(2+). In contrast to the RYR1 isoform, the cardiac RYR2 isoform was unaffected by dantrolene, both in native cardiac SR vesicles and when heterologously expressed in HEK-293 cells. By comparison, the RYR3 isoform expressed in HEK-293 cells was significantly inhibited by dantrolene, and the extent of RYR3 inhibition was similar to that displayed by the RYR1 in native SR vesicles. Our results thus indicate that both the RYR1 and the RYR3, but not the RYR2, may be targets for dantrolene inhibition in vivo.
Dantrolene inhibits long-term depression and depotentiation of synaptic transmission in the rat dentate gyrus.[Pubmed:8577362]
Neuroscience. 1995 Oct;68(3):621-4.
The involvement of Ca release from intracellular stores in the induction of long-term depression and depotentiation of excitatory synaptic transmission was investigated in the rat dentate gyrus using dantrolene, an agent known to block Ca release via the ryanodine receptor. In control slices, low-frequency stimulation (1 Hz for 15 min) induced robust long-term depression of baseline field excitatory postsynaptic potentials and depotentiation of previously established long-term potentiation. Dantrolene (50 microM) was found to block completely both long-term depression of baseline responses and depotentiation. Moreover, long-term potentiation induced by high-frequency stimulation was enhanced in the presence of dantrolene.
Dantrolene ameliorates the metabolic hallmarks of sepsis in rats and improves survival in a mouse model of endotoxemia.[Pubmed:8159702]
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3039-43.
Sepsis is the systemic inflammatory response resulting from serious infection and is the most common cause of death in intensive care units. Intracellular free calcium concentration ([Ca2+]i) is an important regulator of numerous cellular processes and when increased excessively may act as a potent cellular toxin. To determine if [Ca2+]i is responsible for the major metabolic changes which are hallmarks of sepsis, we examined if sodium dantrolene, a drug which decreases release of calcium from sarcoplasmic reticulum, affected the metabolic abnormalities in plasma and epitrochlearis muscles of rats made septic by cecal ligation and perforation. Dantrolene when added in vitro or when given in vivo decreases many of the metabolic hallmarks of sepsis--i.e., muscle protein breakdown approximately 30%, muscle glucose transport approximately 38%, muscle lactate formation approximately 28%, and plasma lactate approximately 29% (P < 0.05). In addition, we examined the ability of dantrolene to improve survival in a mouse model of endotoxemia. Dantrolene caused > 2-fold improvement in survival when it was administered concurrently with endotoxin (54% vs. 20% survival in dantrolene-treated and control mice, respectively (P < 0.001). Our results are consistent with the hypothesis that an increase in [Ca2+]i plays an important role in the metabolic abnormalities which occur during sepsis and that dantrolene administration may be an effective therapeutic strategy.